Welcome to Fierce Pharma's regulatory tracker for the second half of 2025. | In this tracker, Fierce Pharma is recording the ...

Merck remains a top Big Pharma name with strong leadership, rising sales, and high margins, despite regulatory fears and ...

Although Merck (NYSE:MRK) is confronted with the unavoidable Keytruda patent cliff in 2028, the company is strategically ...

Merck & Co., Inc.'s 4.09% dividend yield and robust pipeline signal strong growth potential. Click here to read an analysis ...

German pharmaceutical giant Merck has completed a €3 billion ($3. 5 billion) takeover of US biopharmaceutical company ...

Iya Khalil, PhD, discusses Merck & Co.’s approach to artificial intelligence (AI), and success in applying the technology, ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...

RFK Jr.’s vaccine panel endorsed Merck’s RSV shot for babies, easing fears that his stance might delay rollout.

Review the current Merck & Co Inc (MRK:XNYS) dividend yield and history to decide if MRK is the best investment for you.

Merck & Co. Inc. closed 40.46% short of its 52-week high of $134.63, which the company reached on June 25th.

Merck & Co., Inc. (NYSE:MRK) is one of the 12 stocks that will make you rich in 10 years. On June 23, the company shared ...

Find out if Merck & Co Inc (MRK:XNYS) stock is overpriced or undervalued based on Morningstar's evaluation. Assess the current comparison of market prices to the Fair Value of the company's share ...